Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | RET | P07949 | 3/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.32 |
| ▸ | ATR | Q13535 | 2/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16100099 | 1.00 | RXRA (0.33) | RXRARXRBRXRGCA12CA1 | |
| SCHEMBL298676 | 0.85 | CYP4F2 (0.36) | RXRARXRBRXRGCA12CA1 | |
| SCHEMBL16100337 | 0.85 | CYP4F2 (0.36) | RXRARXRBRXRGCA12CA1 | |
| SCHEMBL23611666 | 0.84 | — | — | |
| SCHEMBL23611664 | 0.84 | — | — | |
| SCHEMBL16100139 | 0.83 | RXRA (0.37) | RXRARXRBRXRGCA12CA1 | |
| SCHEMBL16100137 | 0.83 | RXRA (0.37) | RXRARXRBRXRGCA12CA1 | |
| SCHEMBL26741104 | 0.83 | RXRA (0.35) | RXRARXRBRXRGCA12CA1 | |
| SCHEMBL29925580 | 0.83 | RXRA (0.35) | RXRARXRBRXRGCA12CA1 | |
| SCHEMBL25619321 | 0.82 | POLB (0.37) | RXRARXRBRXRGRETCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115043844-B | TRK kinase inhibitor compounds and uses thereof | 河南迈英诺医药科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-115043844-A | TRK kinase inhibitor compounds and uses thereof | 河南迈英诺医药科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9943504-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| EP-2970220-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014153235-A2 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | RXRA 2291/4885RXRB 1815/4885RXRG 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.